Denmark-based Novo Nordisk has introduced Ryzodeg (insulin degludec/insulin aspart) in Mexico, which will be used to treat adult patients suffering from type 2 diabetes.
The launch makes Mexico the first country in the world where Ryzodeg will be available.
Go deeper with GlobalData
Ryzodeg is a combination of insulin degludec and insulin aspart in the ratio of 70% and 30%.
Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: "Ryzodeg is a new approach to diabetes management, and we are very pleased to make it available now for people with diabetes.
"Ryzodeg has documented excellent glucose control and a low risk of hypoglycaemia in clinical trials, and it represents an excellent opportunity for intensification of insulin treatment with fewer injections than other treatment options."
The company plans to launch Ryzodeg in more countries around the globe by 2015.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNovo said that the drug when delivered twice daily at main meals offered a reduction in HbA1c, with lower risk of hypoglycaemia against biphasic insulin aspart 30.
Ryzodeg has received approval in Aruba, Brazil, Chile, Costa Rica, El Salvador, the EU, Hong Kong, Iceland, India, Israel, Japan, Kazakhstan, Macedonia, Mexico, Norway, Russia, South Korea and Switzerland.
Novo has enrolled around 11,000 people in the clinical trial programmes for insulin degludec (BEGIN) and Ryzodeg (BOOST).
With around 40,700 employees in 75 countries, Novo sells its products in 180 countries.
